Key clinical point: In a new trial analysis, an implantable alert device relative to a sham identified silent MIs and avoided false positive ER visits.
Major finding: False-positive ER visits fell from 0.678 when device was off to 0.164/year (P less than .001) when device was activated.
Data source: ALERTS, a multicenter, randomized controlled trial
Disclosures: Dr. Gibson has financial relationships with many companies, including Angel Medical Systems, the sponsor of this trial.
REPORTING FROM CRT 2019
This Week's Must Reads
Must Reads in Acute Coronary Syndromes
hsCRP Levels & Adverse CE Events After ACS, JAMA Cardiol; ePub 2019 Mar 6; Mani, et al
Predischarge Cardiac Testing in a Chest Pain Unit, Am J Cardiol; ePub 2019 Mar 8; Howell, et al
Serum Uric Acid, Silent MI & Mortality, Am J Cardiol; ePub 2018 Dec 19; Ahmad, et al